{"database": "press", "table": "releases", "rows": [["https://budzinski.house.gov/posts/budzinski-champions-fda-approval-of-first-ever-treatment-for-sanfilippo-syndrome-type-a", "Budzinski Champions FDA Approval of First-Ever Treatment for Sanfilippo Syndrome Type A", "2026-09-18", "2026", "2026-09", "Democrat", "House", "IL", "Nikki Budzinski", "B001315", "budzinski.house.gov", "budzinski", "https://budzinski.house.gov/press", "scraper", "Last August, after learning of Lottie\u2019s story, Budzinski sent a letter to the FDA encouraging the agency to expedite its review of the resubmitted application for the therapy, warning that standard review timelines don\u2019t match the urgency families like the Milburns are facing. \u201cHistorically, BLA reviews can take up to six months \u2014 time that many families simply don\u2019t have,\u201d Budzinski wrote at the time. \u201cActing swiftly to approve UX111 could save the lives of thousands of children who are running out of time.\u201d\n\nAfter months of advocacy at FDA, the decision is welcome news for residents in Illinois\u2019 13th District. \u201cI\u2019m so grateful to the Milburns for working with my office on pushing the FDA to expedite approval of this potentially life-saving treatment,\u201d said Congresswoman Budzinski. \u201cLottie and families across the Sanfilippo community have been waiting for a real treatment option for far too long. I\u2019m glad the FDA moved on this, and my team and I will keep working alongside the Milburn family and the Cure Sanfilippo Foundation as they navigate what comes next.\u201d\n\nThe Milburn family, who has been in regular contact with Budzinski\u2019s office throughout the process, released the following statement: \u201cThe approval of UX111 (now FAYUVI) is not just incredible news for families like ours, but a historical moment for the Sanfilippo community as it is the first ever FDA approved treatment for any type of MPS III. Now, we wait to learn more about our daughter, Lottie\u2019s, eligibility to receive the treatment. We are hopeful the label for FAYUVI will remain broad so all patients who need the treatment may receive it.\n\nBackground: MPS III is a rare, inherited disease that progressively damages the brain and nervous system, causing children to lose cognitive, language, and other developmental abilities over time. Until this week, treatment was limited to managing symptoms, with no approved therapy that changed the underlying course of the disease. FAYUVI is a one-time gene therapy that delivers a working copy of the SGSH gene, enabling the body to produce the enzyme MPS IIIA patients are missing.The FDA granted the therapy Orphan Drug, Fast Track, and Breakthrough Therapy designations, and approved it for Ultragenyx Pharmaceutical, Inc.Budzinski\u2019s full August 2025 letter to the FDA is available HERE.", 1, "2026-11-10T13:17:37Z", "2026-11-10T13:18:48Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://budzinski.house.gov/posts/budzinski-champions-fda-approval-of-first-ever-treatment-for-sanfilippo-syndrome-type-a"], "units": {}, "query_ms": 1.2940759770572186, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}